FUCIDIN H 1 % — DIN 02238578
HYDROCORTISONE ACETATE : 1 % FUSIDIC ACID : 2 % · LEO PHARMA INC · CREAM · wholesale supply in Canada
Health Canada status: MARKETED
What is FUCIDIN H?
FUCIDIN H 1 % contains HYDROCORTISONE ACETATE : 1 % FUSIDIC ACID : 2 %. It is listed in the Health Canada Drug Product Database under DIN 02238578, held by LEO PHARMA INC, supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 11-Nov-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FUCIDIN H used for?
Treatment of mild to moderately severe atopic dermatitis where Staphylococcus aureus is suspected as a contributing factor. Has antibacterial and anti-inflammatory activity.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Hydrocortisone And Antibiotics cost around the world?
Hydrocortisone And Antibiotics is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 11 | 71 | USD███.██ |
| South Africa | single exit price | 15 | 22 | ZAR███.██ |
| Saudi Arabia | public | 16 | 16 | SAR███.██ |
| Greece | producer price (ex-factory) | 15 | 15 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 9 | 9 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 5 | 9 | CZK███.██ |
| Australia | ex-manufacturer | 4 | 8 | AUD███.██ |
| United Arab Emirates | public | 4 | 6 | AED███.██ |
| Bahrain | retail (max) | 4 | 6 | BHD███.██ |
| Morocco | PPV (public price) | 5 | 6 | MAD███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Iceland | max wholesale | 3 | 3 | ISK███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 2 | NOK███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
183 pack listings across 103 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every Hydrocortisone And Antibiotics pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Hydrocortisone And Antibiotics in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Hydrocortisone And Antibiotics, across 7 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ENDO OPERATIONS LTD. | 1 | 1 | VIOFORM HYDROCORTISONE | Sourceable in Canada |
| LEO PHARMA INC | 1 | 1 | FUCIDIN H | Sourceable in Canada |
| PFIZER CANADA ULC | 2 | 0 | NEO-CORTEF 0.5% OINTMENT, NEO-CORTEF 1% OINTMENT | No marketed DIN |
| CIBA PHARMACEUTICALS, CIBA-GEIGY CANADA LTD. | 1 | 0 | VIOFORM + HYDROCORTISONE | No marketed DIN |
| GLAXOSMITHKLINE INC | 1 | 0 | CORTISPORIN | No marketed DIN |
| NOVARTIS PHARMACEUTICALS CANADA INC | 1 | 0 | VIOFORM HYDROCORTISONE MILD | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 % |
|---|---|
| Dosage form | CREAM |
| Route | TOPICAL |
| Pack configuration (monograph) | 30 g aluminium tubes covered with internal epoxyphenol lacquer, with re-closable high density polyethylene screw cap. |
| Storage | Store below 30 °C. Use within 3 months of first opening the tube. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Hydrocortisone And Antibiotics |
|---|---|
| ATC code | D07CA01 |
| AHFS class | 84:06.00 ; 84:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02238578 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2238578 |
| Brand name | FUCIDIN H |
| Generic / active ingredient | HYDROCORTISONE ACETATE : 1 % FUSIDIC ACID : 2 % |
| Market authorization holder | LEO PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | D07CA01 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D07CA |
| Current status | MARKETED |
| Status date | 11-Nov-1998 |
| Original market date | 1998-11-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply 3 times daily and gently massage into affected areas. Treatment period in clinical trials was 14 days; consider shorter course if symptoms improve.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ingredients; primary skin infections (fungal, viral, bacterial) untreated/uncontrolled; tuberculosis skin manifestations; vaccination eruptions; perioral dermatitis; rosacea.
Warnings and precautions
Avoid long-term use (>14 days). Risk of HPA axis suppression, Cushing’s syndrome, and antibiotic resistance. Avoid contact with eyes (risk of glaucoma/cataracts).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| VIOFORM HYDROCORTISONE | 3 % | CREAM | ENDO OPERATIONS LTD. | MARKETED | 00074500 |
| CORTISPORIN | 5 MG | OINTMENT | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 00666246 |
| NEO-CORTEF 0.5% OINTMENT | 0.5 % | OINTMENT | PFIZER CANADA ULC | CANCELLED POST MARKET | 00194891 |
| NEO-CORTEF 1% OINTMENT | 0.5 % | OINTMENT | PFIZER CANADA ULC | CANCELLED POST MARKET | 00194913 |
| VIOFORM + HYDROCORTISONE | 1 % | OINTMENT | CIBA PHARMACEUTICALS, CIBA-GEIGY CANADA LTD. | CANCELLED POST MARKET | 00074527 |
| VIOFORM HYDROCORTISONE MILD | 3 % | CREAM | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 00074489 |
2 · Same class — other molecules in ATC D07CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Hydrocortisone And Antibiotics | CORTISPORIN · FUCIDIN H · NEO-CORTEF 0.5% OINTMENT · NEO-CORTEF 1% OINTMENT · +3 more | 7 | 2 | Yes |
| Methylprednisolone And Antibiotics | NEO-MEDROL | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D07C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D07CB | Flumetasone And Antibiotics · Triamcinolone And Antibiotics | 13 | 5 |
| D07CC | Betamethasone And Antibiotics · Fluocinonide And Antibiotics | 6 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FUCIDIN H called?
The same molecule, Hydrocortisone And Antibiotics, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Alfacort | Latin | Bahrain, Saudi Arabia, United Arab Emirates |
| HYDROCORTISON VUAB | Latin | Czechia |
| Dilucort | Latin | South Africa |
| HYDROCORTISONE LEURQUIN | Latin | Morocco |
| Macleods Hydrocortisone Injection | Latin | South Africa |
| Softacort | Latin | Czechia, Iceland |
| Terracortril | Latin | South Africa |
| Acecort | Latin | Norway |
| CANDICORT CREAM | Latin | Saudi Arabia |
| COLIRCUSI H.C WITH NEOM | Latin | Saudi Arabia |
| CORTIDERM | Latin | Bahrain |
| Cortotic Vet | Latin | Iceland |
| Covocort | Latin | South Africa |
| Daktacort | Latin | South Africa |
| EFFICORT HYDROPHILE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.